[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J: O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer; 2003 Oct 20;89(8):1517-23
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
  • In a retrospective study, O(6)-methylguanine-DNA-methyltransferase (MGMT) expression was analysed by immunohistochemistry using monoclonal human anti-MGMT antibody in melanoma metastases in patients receiving dacarbazine (DTIC) as single-drug therapy or as part of combination chemotherapy with DTIC-vindesine or DTIC-vindesine-cisplatin.
  • The correlation of MGMT expression levels with clinical response to chemotherapy was investigated in 79 patients with metastatic melanoma.
  • There was an inverse relationship between MGMT expression and clinical response to DTIC-based chemotherapy (P=0.05).
  • Polymorphisms in the coding region of the MGMT gene were also investigated in tumours from 52 melanoma patients by PCR/SSCP and nucleotide sequence analyses.
  • There were no differences in the frequencies of these polymorphisms between these melanoma patients and patients with familial melanoma or healthy Swedish individuals.
  • There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein.
  • All melanoma patients with the MGMT 53/84 polymorphism except one had tumours with high MGMT expression.
  • There was no significant correlation between any of the MGMT polymorphisms and clinical response to chemotherapy, although an indication of a lower response rate in patients with SNPs in exon 5 was obtained.
  • Thus, MGMT expression appears to be more related to response to chemotherapy than MGMT polymorphisms in patients with metastatic melanoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / pharmacology. Gene Expression Regulation, Neoplastic. Melanoma / drug therapy. Melanoma / genetics. O(6)-Methylguanine-DNA Methyltransferase / biosynthesis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymorphism, Genetic. Skin Neoplasms / drug therapy. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / pharmacology. Cisplatin / administration & dosage. Cisplatin / pharmacology. Female. Humans. Male. Middle Aged. Treatment Outcome. Vindesine / administration & dosage. Vindesine / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):248-52 [10629085.001]
  • [Cites] Oncology. 2002;63(4):393-7 [12417795.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Gene. 1989 Apr 15;77(1):51-9 [2744487.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6119-29 [2205376.001]
  • [Cites] Bioessays. 1994 Nov;16(11):833-9 [7840761.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):693-7 [8637727.001]
  • [Cites] Pharmacogenetics. 1996 Aug;6(4):361-3 [8873223.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5571-5 [8971155.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):129-34 [9071912.001]
  • [Cites] Biochemistry. 1997 May 13;36(19):5769-76 [9153417.001]
  • [Cites] Int J Cancer. 1997 May 29;71(5):719-23 [9180136.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5093-9 [9371508.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):10863-7 [9556560.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1199-202 [9820180.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1368-74 [9849419.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):744-50 [10048977.001]
  • [Cites] Pharmacogenetics. 1999 Feb;9(1):81-7 [10208646.001]
  • [Cites] Hum Gene Ther. 1999 Apr 10;10(6):1021-30 [10223735.001]
  • [Cites] Mutagenesis. 1999 May;14(3):339-47 [10375003.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):388-95 [10404091.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1467-74 [10454526.001]
  • [Cites] Cancer Res. 1987 Dec 1;47(23):6229-35 [2824027.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Dec;291(3):1269-75 [10565851.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Mar;19(1):21-34 [10840932.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):664-71 [10900246.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] Biochem J. 2000 Oct 15;351 Pt 2:393-402 [11023825.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34197-204 [10942771.001]
  • [Cites] Mol Ther. 2001 Jan;3(1):78-87 [11162314.001]
  • [Cites] Int J Cancer. 2001 Apr 1;92(1):123-9 [11279615.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1398-409 [11350911.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1797-802 [12087469.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):335-42 [12170182.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Aug;50(2):160-2 [12172983.001]
  • [Cites] Hum Mutat. 2002 Nov;20(5):408-9 [12402349.001]
  • [Cites] Pharmacogenetics. 2000 Feb;10(1):59-66 [10739173.001]
  • (PMID = 14562026.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 7GR28W0FJI / Dacarbazine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  • [Other-IDs] NLM/ PMC2394337
  •  go-up   go-down


2. Dalle S, Martin-Denavit T, Thomas L: [Genotypic hypervariability of melanoma: a therapeutic challenge]. Med Sci (Paris); 2006 Feb;22(2):178-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genotypic hypervariability of melanoma: a therapeutic challenge].
  • [Transliterated title] Hypervariabilité génotypique des mélanomes: un défi thérapeutique.
  • Cutaneous melanoma remains a management challenge.
  • Melanoma is the leading cause of death from skin tumors worldwide.
  • Melanoma progression is well defined in its clinical, histopathological and biological aspects, but the molecular mechanism involved and the genetic markers associated to metastatic dissemination are only beginning to be defined.
  • The recent development of high-throughput technologies aimed at global molecular profiling of cancer is switching on the spotlight at previously unknown candidate genes involved in melanoma.
  • Among those genes, BRAF is one of the most supposed to be of interest and targeted therapies are ongoing in clinical trials.
  • In familial melanoma, germline mutations in two genes, CDKN2A and CDK4, that play a pivotal role in controlling cell cycle and division.
  • It is hope that this better understanding of the biologic features of melanoma and the mechanisms underlying tumor-induced immunosuppression will lead to efficaceous targeted therapy.
  • [MeSH-major] Genetic Heterogeneity. Melanoma / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Division. Cyclin-Dependent Kinase 4 / genetics. Cyclin-Dependent Kinase 4 / physiology. Cyclin-Dependent Kinase Inhibitor p16 / physiology. Drug Design. France / epidemiology. Genes, p16. Genes, p53. Genotype. Humans. MAP Kinase Signaling System. Models, Biological. Mutation. Neoplasm Metastasis. Neoplastic Syndromes, Hereditary / genetics. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / physiology. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins B-raf / physiology. Receptor, Melanocortin, Type 1 / genetics. Receptor, Melanocortin, Type 1 / physiology. Tumor Suppressor Protein p53 / physiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457759.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptor, Melanocortin, Type 1; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 37
  •  go-up   go-down


3. van Bussel B, Pijpers E, Ferreira I, Castermans P, Kruseman AN: Polymorbidity in diabetes in older people: consequences for care and vocational training. Postgrad Med J; 2007 Dec;83(986):763-7
MedlinePlus Health Information. consumer health - Diabetes Complications.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the prevalence of complicating and concurrent morbidities in older diabetic patients and to evaluate to what extent their occurrence affects the burden of disease and use of medical healthcare.
  • Healthcare registration systems were used to retrieve data on 300 patients with diabetes aged >or=60 years who, according to the severity of their disease and intensity of care required, were treated in a regional general practitioner (GP), diabetes nurse specialist (DNS) or medical specialist (MS) practice.
  • RESULTS: Complicating and concurrent morbidities were often found irrespective of the type of practice involved.
  • After adjustments for differences in sex, age and glycosylated haemoglobin (HbA1c), the extent of complicating comorbidities showed sequential increases in patients managed by GP, DNS and MS (mean number of 3.6, 4.7 and 6.7, respectively; p(trend)<0.001).
  • Both complicating and concurrent comorbidities were similarly associated with the extent of drug use (beta = 0.49 (95% CI 0.40 to 0.58) and beta = 0.57 (95% CI 0.52 to 0.72), respectively) and the number of consultations with specialists other than the main care giver (beta = 1.19 (95% CI 1.15 to 1.24) and beta = 1.21 (95% CI 1.14 to 1.28), respectively).
  • CONCLUSIONS: The use of healthcare facilities by older patients with diabetes is substantial, irrespective of the complexity of the disease and the kind of practice involved.
  • The common manifestation of complicating and concurrent comorbidities and their varying complexity in individual patients requires a patient-oriented rather than a disease-oriented approach and vocational training programmes for care givers that are tailored to the complexity of multiple chronic diseases.
  • [MeSH-major] Diabetes Complications / therapy
  • [MeSH-minor] Aged. Blood Glucose. Chronic Disease. Cost of Illness. Cross-Sectional Studies. Female. Humans. Hypoglycemic Agents / therapeutic use. Male. Middle Aged. Patient Acceptance of Health Care. Polypharmacy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2000 Feb 26;320(7234):569-72 [10688568.001]
  • [Cites] Med Care. 2007 Jan;45(1):55-65 [17279021.001]
  • [Cites] J Clin Epidemiol. 2001 Jul;54(7):680-6 [11438408.001]
  • [Cites] BMJ. 2001 Oct 27;323(7319):983-5 [11679390.001]
  • [Cites] BMJ. 2002 Oct 26;325(7370):925 [12399340.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Clin Epidemiol. 1993 May;46(5):469-73 [8501473.001]
  • [Cites] J Clin Epidemiol. 1994 Nov;47(11):1245-51 [7722560.001]
  • [Cites] Control Clin Trials. 1998 Dec;19(6):589-601 [9875838.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2870-4 [15625341.001]
  • [Cites] BMJ. 2005 Mar 19;330(7492):609-10 [15774963.001]
  • [Cites] BMJ. 2005 Mar 19;330(7492):662-5 [15775001.001]
  • [Cites] Acad Med. 2005 May;80(5):507-12 [15851467.001]
  • [Cites] Am J Med. 2005 Jun;118(6):680-5; discussion 685-7 [15922702.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):474-80 [15998827.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):716-24 [16091574.001]
  • [Cites] Health Qual Life Outcomes. 2005;3:74 [16305743.001]
  • [Cites] Chest. 2006 Feb;129(2):285-91 [16478843.001]
  • [Cites] Lancet. 2006 Feb 18;367(9510):550-1 [16488782.001]
  • [Cites] BMC Health Serv Res. 2006;6:84 [16820048.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):13-22 [17242667.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):453-71 [10717521.001]
  • (PMID = 18057176.001).
  • [ISSN] 1469-0756
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hypoglycemic Agents
  • [Other-IDs] NLM/ PMC2750927
  •  go-up   go-down


Advertisement
4. Jones C, Plummer ER: PARP inhibitors and cancer therapy - early results and potential applications. Br J Radiol; 2008 Oct;81 Spec No 1:S2-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PARP inhibitors and cancer therapy - early results and potential applications.
  • This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Poly(ADP-ribose) Polymerase Inhibitors
  • [MeSH-minor] Animals. Antineoplastic Agents, Alkylating / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Melanoma / drug therapy. Mice. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819994.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


5. Chuang KH, Cheng CM, Roffler SR, Lu YL, Lin SR, Wang JY, Tzou WS, Su YC, Chen BM, Cheng TL: Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Bioconjug Chem; 2006 May-Jun;17(3):707-14
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
  • Combination therapy can help overcome limitations in the treatment of heterogeneous tumors.
  • In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells.
  • Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo.
  • Dansyl moieties were covalently attached to recombinant beta-glucuronidase (betaG) and interleukin 2 (IL-2) via a flexible poly(ethylene glycol) linker to form DNS-PEG-betaG and DNS-PEG-IL-2 conjugates.
  • The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells).
  • DNS-PEG-betaG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration.
  • Systemic administration of DNS-PEG-IL-2 or DNS-PEG-betaG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors.
  • Combination treatment with DNS-PEG-betaG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen.
  • These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Glucuronidase / pharmacology. Haptens / immunology. Interleukin-2 / pharmacology. Neoplasms / drug therapy. Neoplasms / immunology. Prodrugs / metabolism
  • [MeSH-minor] Animals. Antibodies / immunology. Cell Line, Tumor. Drug Therapy, Combination. Mice. Mice, Inbred BALB C. Polyethylene Glycols / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704208.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antineoplastic Agents; 0 / Haptens; 0 / Interleukin-2; 0 / Prodrugs; 30IQX730WE / Polyethylene Glycols; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


6. Raza ML, Zeeshan M, Ahmad M, Shaheen F, Simjee SU: Anticonvulsant activity of DNS II fraction in the acute seizure models. J Ethnopharmacol; 2010 Apr 21;128(3):600-5
Hazardous Substances Data Bank. ACETONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticonvulsant activity of DNS II fraction in the acute seizure models.
  • Other species of Delphinium are reported as anticonvulsant and are traditionally used in the treatment of epilepsy.
  • DNS II acetone was chosen for further testing in the acute seizure models of epilepsy to study the antiepileptic potential in male mice.
  • MATERIALS AND METHODS: Different doses (60, 65 and 70mg/kg, i.p.) of DNS II acetone fraction of Delphinium nordhagenii was administered 30min prior the chemoconvulsant's injection in the male mice.
  • Moreover, four different doses of DNS II (60, 65, 70 and 100mg/kg, i.p.) were tested in the MES test.
  • RESULTS: The DNS II acetone fraction of Delphinium nordhagenii has exhibited the anticonvulsant actions by preventing the seizures against PTZ- and picrotoxin-induced seizure as well as 100% seizure protection in MES test.
  • [MeSH-major] Anticonvulsants / therapeutic use. Epilepsy / drug therapy. Epilepsy / prevention & control. Seizures / drug therapy. Seizures / prevention & control
  • [MeSH-minor] Acetone / therapeutic use. Animals. Delphinium / chemistry. Diazepam / therapeutic use. Male. Melanoma / drug therapy. Mice. Mice, Inbred Strains. Pakistan. Pentylenetetrazole / therapeutic use. Phenytoin / therapeutic use. Picrotoxin / therapeutic use. Ranunculaceae / chemistry. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. PICROTOXIN .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138136.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anticonvulsants; 124-87-8 / Picrotoxin; 1364PS73AF / Acetone; 6158TKW0C5 / Phenytoin; Q3JTX2Q7TU / Diazepam; WM5Z385K7T / Pentylenetetrazole
  •  go-up   go-down


7. Steed ME, Vidaillac C, Rybak MJ: Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother; 2010 Dec;54(12):5187-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although infections with daptomycin-nonsusceptible (DNS) MRSA are infrequent, optimal therapy of these strains has not been determined.
  • We investigated the killing effects of novel antibiotic combinations with daptomycin (DAP) against two clinical DNS MRSA isolates (SA-684 and R6003) in a 72-h in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations (SEV).
  • The unique combination of DAP plus TMP/SMX was the most effective and rapidly bactericidal regimen against the two isolates tested and may provide a clinical option to treat DNS S. aureus infections.
  • [MeSH-major] Anti-Infective Agents / pharmacology. Daptomycin / pharmacology. Methicillin-Resistant Staphylococcus aureus / drug effects
  • [MeSH-minor] Acetamides / pharmacology. Cephalosporins / pharmacology. Drug Combinations. Endocarditis, Bacterial / microbiology. Linezolid. Microbial Sensitivity Tests. Nafcillin / pharmacology. Oxazolidinones / pharmacology. Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology

  • MedlinePlus Health Information. consumer health - MRSA.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. NAFCILLIN .
  • Hazardous Substances Data Bank. LINEZOLID .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Ther. 2000 Jan;22(1):66-75 [10688391.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Oct;53(10):4127-32 [19635961.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Feb;45(2):454-9 [11158740.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jun;45(6):1799-802 [11353628.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jun;45(6):1843-6 [11353635.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Aug;46(8):2606-12 [12121940.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Aug;47(8):2682-4 [12878541.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jan;48(1):63-8 [14693519.001]
  • [Cites] J Antimicrob Chemother. 1985 Jan;15 Suppl A:125-30 [3980323.001]
  • [Cites] Antimicrob Agents Chemother. 1987 Dec;31(12):1982-8 [3439805.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Dec;36(12):2709-14 [1336344.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72 [15561842.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jan;49(1):302-8 [15616309.001]
  • [Cites] Ann Pharmacother. 2005 Mar;39(3):427-32 [15701775.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jul;49(7):2735-45 [15980344.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45 [16723576.001]
  • [Cites] Int J Antimicrob Agents. 2006 Oct;28(4):280-7 [16963232.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Oct;50(10):3245-9 [17005801.001]
  • [Cites] Diagn Microbiol Infect Dis. 2007 Apr;57(4):459-65 [17240105.001]
  • [Cites] J Antimicrob Chemother. 2007 Aug;60(2):334-40 [17540670.001]
  • [Cites] Clin Infect Dis. 2007 Sep 1;45(5):601-8 [17682996.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8 [17620372.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jan;52(1):269-78 [17954690.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Mar;52(3):831-6 [17999971.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):433-7 [18214559.001]
  • [Cites] Diagn Microbiol Infect Dis. 2008 Jun;61(2):235-9 [18314293.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2223-5 [18378708.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2156-62 [18411321.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Sep;52(9):3061-7 [18591272.001]
  • [Cites] J Antimicrob Chemother. 2008 Dec;62(6):1305-10 [18801920.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Dec 1;178(11):1180-5 [18787216.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jun;53(6):2636-7 [19289517.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8 [19332678.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Sep;53(9):3981-4 [19564361.001]
  • [Cites] Diagn Microbiol Infect Dis. 2009 Oct;65(2):158-62 [19748426.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jul;44(7):1925-9 [10858356.001]
  • (PMID = 20921318.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Infective Agents; 0 / Cephalosporins; 0 / Drug Combinations; 0 / Oxazolidinones; 4CNZ27M7RV / Nafcillin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 807PW4VQE3 / cefepime; ISQ9I6J12J / Linezolid; NWQ5N31VKK / Daptomycin
  • [Other-IDs] NLM/ PMC2981245
  •  go-up   go-down


8. Turner C, Pateman B: A study of district nurses' experiences of continuous ambulatory chemotherapy. Br J Community Nurs; 2000 Aug;5(8):396-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of district nurses' experiences of continuous ambulatory chemotherapy.
  • As a result of technical developments and policies that promote shorter hospital stays, patients are increasingly receiving high technology treatment in the community.
  • The administration of ambulatory intravenous chemotherapy at home is an example of such treatment.
  • Despite being generalist nurses, district nurses (DNs) are involved in what could be viewed as 'specialist' care - advising and supporting patients while they are receiving treatment.
  • This article reports on a study of 20 DNs from one community trust and examines the sources of the knowledge and skills used in caring for these patients and the communication links with the regional cancer centre.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Community Health Nursing. Home Infusion Therapy / nursing. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12271233.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Ravot E, Comolli G, Lori F, Lisziewicz J: High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment. J Gene Med; 2002 Mar-Apr;4(2):161-9
Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment.
  • BACKGROUND: Gene therapy has recently been advanced by the development of HIV-based vectors that are able to transduce some non-dividing cells.
  • In this study, a novel delivery strategy is developed to improve significantly the efficiency of HIV-based vectors in transducing non-dividing cells.
  • METHODS: Mature human monocyte-derived macrophages (14-21 days old) were transduced at a low multiplicity of infection (MOI) of HIV vectors carrying a reporter gene. dNSs were added to the medium during transduction (5 mM dNS) and immediately before post-transduction culture (2.5 mM dNS).
  • RESULTS: The addition of dNS to the medium significantly enhanced the efficiency of transduction of human macrophages by HIV-based vectors.
  • The percentage of cells expressing the transgene rose up to 50% in the presence of dNS, increasing the basal transduction levels up to 35-fold (average=10.8-fold).
  • Furthermore, treatment with dNTP precursors compensated for the wide inter-donor variability, allowing the highest enhancement effects in donors with the lowest basal transduction efficiencies.
  • CONCLUSIONS: This is the first demonstration that a single treatment of non-dividing target cells with exogenous dNS can enhance the efficiency of lentiviral-mediated transduction of cells, allowing for high efficiency gene transfer.
  • This simple approach might be transferred to a broader range of quiescent cell types that are scarcely susceptible to lentiviral-based gene delivery due to low dNTP levels.
  • [MeSH-minor] 3T3 Cells. Animals. Cell Division. Cell Line. Dose-Response Relationship, Drug. HIV / genetics. Humans. Macrophages / metabolism. Mice. Retroviridae / genetics. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Time Factors. Transduction, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 11933217.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 533-67-5 / Deoxyribose
  •  go-up   go-down


10. Ren L, Lv SX, Zhong YS, Xu JM, Wei Y, Fan J, Qin LX, Wang JH, Cheng JM, Qian S, Qin XY: [Prognostic analysis of 669 liver metastasis of colorectal cancer cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jul;12(4):337-41
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the relation between different therapy and survival rate of liver metastasis of colorectal cancer (LMCC).
  • RESULTS: Of the 669 cases, 379 cases were synchronous liver metastases(SLM) and 290 cases were metachronous liver metastases(MLM).
  • There were no significant differences in age, gender and position of primary tumor between SLM and MLM groups(P>0.05), but as to liver metastasis characteristics(liver lobe involved, focus number and maximal focus diameter) and CEA, CA19-9 before therapy,there were significant differences(P<0.05).
  • Two hundred and fifty-three cases underwent curative hepatic resection, including 123 cases in SLM and 130 cases in MLM.
  • The median survival time of SLM was(11+/-1) months and of MLM(23+/-2) months(P<0.01).
  • Five-year survival rate of SLM was 6.4% and of MLM 11.4%(P<0.01).
  • As to different treatments, median survival time and 5-year survival rate of curative hepatic resection group were 37 months and 35.6%, and of non-operation groups(i.e. intervention, chemotherapy, radiofrequency therapy and percutaneous ethanol injection) were 5 to 26 months and 0 to 3.6% respectively(P<0.05).
  • Resection rate and survival of MLM are better than those of SLM.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19598013.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


11. Shiose Y, Kuga H, Ohki H, Ikeda M, Yamashita F, Hashida M: Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates. Bioconjug Chem; 2009 Jan;20(1):60-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates.
  • The primary purpose of this study was to comprehensively delineate specificity of the peptide spacer sequence to tumor-expressed proteases for the design of macromolecular carrier-peptide spacer-drug conjugate system.
  • 225 conjugates of carboxymethyldextran polyalcohol (CM-Dex-PA) as water-soluble carrier and a dansyl derivative (N-(4-aminobutyl)-5-(dimethylamino)-1-naphthalenesulfonamide, DNS) as the model drug linked with different tetrapeptide spacers (Gly-Gly-P(2)-P(1), P(2), P(1): Ala, Asn, Gly, Cit, Gln, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) were combinatorially synthesized.
  • First, the drug release assay of all of the fluorogenic model conjugates was performed in murine Meth A solid tumor homogenates.
  • The drug release rate was higher with conjugates having hydrophobic amino acids at P(2).
  • It was also found that conjugates with Asn release the drug rapidly and, in contrast, those with Pro does not.
  • Second, we selected three peptide spacers (Gly-Gly-Phe-Gly, Gly-Gly-Ile-Gly, Gly-Gly-Pro-Leu), which release only DNS at different rates, and applied them to doxorubicin (DXR) conjugates.
  • These three DXR conjugates were used for investigating relationships with drug release, pharmacokinetics, and antitumor activity against Meth A bearing mice of these conjugates.
  • The release of DXR from the conjugates corresponded well with that of DNS conjugates in tumor homogenates.
  • Taken with the fact that the drug release rate in tumor homogenates was approximately 10-fold different between these two DXR conjugates, it is likely that cellular uptake of the conjugate would be rate-limiting, rather than the drug release process under the in vivo situation.
  • However, much weaker antitumor activity was observed with CM-Dex-PA-Gly-Gly-Pro-Leu-DXR, of which the drug release was extremely slow.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigens, Neoplasm. Drug Carriers / chemistry. Drug Carriers / pharmacokinetics. Histocompatibility Antigens. Mice. Neoplasms / drug therapy. Treatment Outcome

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19090781.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Drug Carriers; 0 / Histocompatibility Antigens; 0 / Peptides; 0 / Prodrugs; 0 / tumor-associated transplantation antigen; 80168379AG / Doxorubicin; 9044-05-7 / carboxymethyl dextran; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


12. Xu JM, Qin XY, Zhong YS, Wei Y, Fan J, Zhou J, Qin LX, Wang JH, Yan ZP, Cheng JM, Wu ZH: [Survival of patients with liver metastasis from colorectal cancer by different modes of therapy: a report of 363 cases]. Zhonghua Zhong Liu Za Zhi; 2007 Jan;29(1):54-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival of patients with liver metastasis from colorectal cancer by different modes of therapy: a report of 363 cases].
  • OBJECTIVE: To evaluate the correlation between different therapies and survival of liver metastasis from colorectal cancer ( LMCC) , and to compare the clinical outcome of synchronous liver metastasis (SLM) with that of metachronous liver metastasis (MLM).
  • METHODS: The clinical data of 363 patients with LMCC were retrospectively reviewed with focus on the correlation between different therapy and survival.
  • RESULTS: Of these 363 patients, 160 had SLM and 203 had MLM.
  • Between the SLM and MLM group, there was no significant difference in age, or gender or primary cancer site (P > 0.
  • 05 ), but significant differences were observed in condition of liver metastasis including liver lobe involved, focus number, maximum focus diameters and level of serum CEA and CA199 before therapy(P <0. 05).
  • Ninety-one patients underwent curative hepatic resection, 22 of them in the SLM group and 69 in the MLM group.
  • 9% (2/69) in MLM group( P < 0.05).
  • 2% with a median survival time of 10 +/- 1 months for the SLM group, and it wasl6.
  • 4% and 17 +/- 1 months for the MLM group (P<0.01).
  • Regarding to the treatment modalities, the 3-year survival rate was 30.
  • 2% with a median survival time of 26 months for curative hepatic resection group, and it was 0% - 16.
  • 7% and 10 - 17 months for non-operation groups treated by intervention, chemotherapy, radiofrequency therapy, percutaneous ethanol injection and Chinese traditional drugs (P <0. 05, P <0. 01 ).
  • [MeSH-major] Colonic Neoplasms / therapy. Liver Neoplasms / therapy. Rectal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Chemoembolization, Therapeutic. Combined Modality Therapy. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Phytotherapy / methods. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575696.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


13. Rojas-Espinosa O, Wek-Rodríguez K, Arce-Paredes P: The effect of exogenous peroxidase on the evolution of murine leprosy. Int J Lepr Other Mycobact Dis; 2002 Sep;70(3):191-200
MedlinePlus Health Information. consumer health - Mycobacterial Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mycobacterium lepraemurium (MLM) is a successful parasite of murine macrophages; in vitro, this microorganism infects macrophages without triggering these cells' ability to produce either the reactive oxygen intermediaries (ROI) or the reactive nitrogen intermediaries (RNI), and ends up lodging within these cells, that, in addition, do not contain myeloperoxidase (MPO).
  • Bacilli were intraperitoneally injected, either alone (MLM) or precoated with horseradish peroxidase (MLM-PO), into two different groups of mice.
  • At two-week intervals, the groups were blood-sampled to measure the levels of antibodies to protein- or lipid-MLM antigens.
  • The extent of the disease was also assessed by looking at the histopathologic changes that occurred both in the liver and the spleen of the infected animals.
  • We found that the animals injected with MLM-PO developed a disease that evolved at a slower pace than the disease that occurred in the animals injected with intact MLM.
  • The difference between groups, both in terms of antibody levels and histological changes, was clearly evident at the intermediate stages of the disease (2 to 2.5 months), but was not so obvious at the more advanced stage of 3 months.
  • Lowering the infective dose of MLM and MLM-PO from 5 x 10(7) bacilli to 5 x 10(6) bacilli would, probably, have resulted in a different outcome of the disease: more extended in the MLM-group than in the MLM-PO group.
  • [MeSH-major] Mycobacterium Infections / drug therapy. Mycobacterium lepraemurium / growth & development. Peroxidase / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12483967.001).
  • [ISSN] 0148-916X
  • [Journal-full-title] International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association
  • [ISO-abbreviation] Int. J. Lepr. Other Mycobact. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


14. Lipkowski AW, Misicka A, Kosson D, Kosson P, Lachwa-From M, Brodzik-Bienkowska A, Hruby VJ: Biological properties of a new fluorescent biphalin fragment analogue. Life Sci; 2002 Jan 11;70(8):893-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper presents data that replacement of the phenylalanine with a dansyl (X=DNS) groups gives an analogue (AA2016) that fully preserves the high affinity of the initial analogue for both mu and delta opioid receptors.
  • Because AA2016 contains a strong fluorescent group, it can be a very useful tool for prospective studies in vivo, including biological barrier permeability, tissue distribution, metabolism and receptor-ligand complex formation.
  • [MeSH-minor] Analgesia. Animals. Dansyl Compounds. Male. Pain / drug therapy. Pain / metabolism. Phenylalanine. Rats. Rats, Wistar. Receptors, Opioid, delta / metabolism. Receptors, Opioid, mu / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11853227.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 06284
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Dansyl Compounds; 0 / Enkephalins; 0 / Fluorescent Dyes; 0 / Receptors, Opioid, delta; 0 / Receptors, Opioid, mu; 47E5O17Y3R / Phenylalanine; 83916-01-2 / biphalin
  •  go-up   go-down


15. Dow GS, Armson A, Boddy MR, Itenge T, McCarthy D, Parkin JE, Thompson RC, Reynoldson JA: Plasmodium: assessment of the antimalarial potential of trifluralin and related compounds using a rat model of malaria, Rattus norvegicus. Exp Parasitol; 2002 Mar;100(3):155-60
Hazardous Substances Data Bank. CHLOROQUINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other DNs which have better absorption characteristics than either trifluralin or oryzalin may offer more scope for antimalarial activity in vivo.
  • [MeSH-major] Malaria / drug therapy. Plasmodium berghei / drug effects. Sulfanilamides. Trifluralin / pharmacology. Trifluralin / therapeutic use
  • [MeSH-minor] Animals. Antimalarials / pharmacology. Antimalarials / therapeutic use. Cells, Cultured. Chloroquine / pharmacology. Chloroquine / therapeutic use. Dinitrobenzenes / pharmacology. Dinitrobenzenes / therapeutic use. Disease Models, Animal. Erythrocytes / parasitology. Parasitic Sensitivity Tests / methods. Rats. Rats, Inbred Lew

  • MedlinePlus Health Information. consumer health - Malaria.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRIFLURALIN .
  • Hazardous Substances Data Bank. ORYZALIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12173400.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Dinitrobenzenes; 0 / Sulfanilamides; 662E385DWH / oryzalin; 886U3H6UFF / Chloroquine; C8BX46QL7K / Trifluralin
  •  go-up   go-down


16. Shah SA, Sajid T, Asif M, Khan F, Haroon T, Malik S, Ghani R: Evaluation of efficacy of management protocol in allergic rhinitis. J Ayub Med Coll Abbottabad; 2007 Jul-Sep;19(3):6-9
Genetic Alliance. consumer health - Allergic rhinitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Allergic rhinitis represents a global health issue affecting between 10% to 25% of the world population, with increasing prevalence, resulting in a significant impact on quality of life, multiple comorbidities and the considerable socio-economic burden.
  • METHOD: This prospective study was conducted in the Department of Ear, Nose & Throat and Head & Neck Surgery, Ayub Teaching Hospital, Abbottabad, over a period of two years (2005 - 2006), to assess the efficacy of a standard protocol of treatment developed and followed in the department.
  • All the patients were prescribed medical treatment, divided into initial phase of 10 days to two weeks duration followed by a maintenance phase, and a regular follow-up schedule was maintained upto two years.
  • 37.53% patients had surgery done for associated pathologies, mostly a DNS.
  • Compliance regarding medication was more than 90% in the initial phase of treatment that dropped to 50% in the maintenance phase.
  • 93% of the patients tolerated the treatment well.
  • Optimal treatment protocol is still lacking especially in the developing countries.
  • Associated problems that may need surgical treatment.
  • Regular follow-up must be ensured to monitor the progress of treatment as well as to identify patients who might be candidates for immunotherapy.
  • Newer modalities of treatment need to be further explored.
  • [MeSH-major] Rhinitis, Allergic, Perennial / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Clinical Protocols. Female. Humans. Infant. Male. Middle Aged. Patient Education as Topic. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444581.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


17. Jen M, Murphy M, Grant-Kels JM: Childhood melanoma. Clin Dermatol; 2009 Nov-Dec;27(6):529-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood melanoma.
  • Pediatric melanoma is rare but increasing in incidence.
  • Because early diagnosis and treatment improves prognosis, clinicians need to include it as a possible diagnosis when evaluating a pigmented lesion in a pediatric patient.
  • Some risk factors for melanoma include xeroderma pigmentosum, giant congenital melanocytic nevi, dysplastic nevus syndrome, atypical nevi, many acquired melanocytic nevi, family history of melanoma, and immunosuppression.
  • Definitive treatment is with surgical excision.
  • Adjuvant therapies such as chemotherapy, immunotherapy, and radiation therapy can be used in advanced cases.
  • [MeSH-major] Melanoma / pathology. Neoplasm Invasiveness / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Age Factors. Biopsy, Needle. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Early Detection of Cancer. Female. Humans. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880040.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 117
  •  go-up   go-down


18. Kolseth SM, Nordhaug DO, Stenseth R, Sellevold O, Kirkeby-Garstad I, Wahba A: Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function. Eur J Cardiothorac Surg; 2009 Dec;36(6):1024-30
Hazardous Substances Data Bank. Norepinephrine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
  • OBJECTIVE: Levosimendan is a calcium-sensitising inotropic agent and a vasodilator used in the treatment of heart failure.
  • We aim at investigating how prophylactic treatment with levosimendan before weaning from cardiopulmonary bypass (CPB) affects postoperative haemodynamics and outcome in patients with low preoperative LVEF.
  • Each patient was matched to a control patient with respect to the following criteria: surgical procedure, EuroSCORE, age, gender and the use of intra-aortic balloon pump.
  • We investigated postoperative haemodynamics in the intensive care unit (ICU) at time points: 1, arrival; 2, approximately 7h after arrival; and 3, the first postoperative morning.
  • No statistically significant differences in cardiac index (CI) (l min(-1)m(-2)), stroke volume index (SVI) (mlm(-2)), mixed venous O(2)-saturation (SvO(2)) (%) or heart rate (HR) (beats per minute) between the two groups measured at the three time points 1-3 were registered.
  • Mean arterial blood pressure (MAP) (mmHg) was lower in the levosimendan group both at time points 2 (68, range: 65-71 vs 75, range: 72-78; p=0.009) and 3 (72, range: 69-74 vs 78, range: 74-82; p=0.01), despite a higher dose of norepinephrine in the treatment group (p=0.021).
  • [MeSH-major] Cardiopulmonary Bypass / adverse effects. Heart Failure / prevention & control. Hydrazones / therapeutic use. Pyridazines / therapeutic use. Vasodilator Agents / therapeutic use. Ventricular Dysfunction, Left / drug therapy
  • [MeSH-minor] Aged. Cardiotonic Agents / therapeutic use. Case-Control Studies. Drug Administration Schedule. Drug Evaluation / methods. Female. Hemodynamics / drug effects. Humans. Male. Middle Aged. Norepinephrine / therapeutic use. Phosphodiesterase Inhibitors / administration & dosage. Phosphodiesterase Inhibitors / therapeutic use. Preanesthetic Medication. Retrospective Studies. Stroke Volume / drug effects

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19592266.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 0 / Hydrazones; 0 / Phosphodiesterase Inhibitors; 0 / Pyridazines; 0 / Vasodilator Agents; 349552KRHK / simendan; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


19. Rainero I, Valfrè W, Gentile S, Lo Giudice R, Ferrero M, Savi L, Pinessi L: A comparison of familial and sporadic migraine in a headache clinic population. Funct Neurol; 2002 Oct-Dec;17(4):193-7
Hazardous Substances Data Bank. Sumatriptan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of familial and sporadic migraine in a headache clinic population.
  • We compared the clinical, psychological and pharmacological characteristics of patients with familial migraine and patients with sporadic migraine.
  • Familial migraine (famM)--at least one first-degree relative affected; B.
  • Four hundred and twenty-four patients (80%) fulfilled the criteria for famM and 106 (20%) for spoM.
  • The patients with famM showed a significantly (p<0.01) earlier age at onset of the disease.
  • Our data suggest that famM and spoM represent a single disease entity.
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Anxiety / psychology. Child. Depression / psychology. Female. Food. Humans. Male. Middle Aged. Migraine with Aura / drug therapy. Migraine with Aura / genetics. Migraine with Aura / psychology. Migraine without Aura / drug therapy. Migraine without Aura / genetics. Migraine without Aura / psychology. Oxazolidinones / therapeutic use. Phenotype. Psychiatric Status Rating Scales. Psychological Tests. Serotonin Receptor Agonists / therapeutic use. Sex Characteristics. Sumatriptan / therapeutic use. Surveys and Questionnaires. Tryptamines

  • Genetic Alliance. consumer health - Migraine.
  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Migraine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12675262.001).
  • [ISSN] 0393-5264
  • [Journal-full-title] Functional neurology
  • [ISO-abbreviation] Funct. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Oxazolidinones; 0 / Serotonin Receptor Agonists; 0 / Tryptamines; 2FS66TH3YW / zolmitriptan; 8R78F6L9VO / Sumatriptan
  •  go-up   go-down






Advertisement